{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:43:00Z","timestamp":1791650580186,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcjo.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:49:02Z","timestamp":1781725742000},"page":"1253-1261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Age-related macular degeneration associated with glucagon-like peptide-1 receptor agonist use: a systematic review"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-3215","authenticated-orcid":false,"given":"Salem Abu","family":"Al-Burak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1453-1056","authenticated-orcid":false,"given":"Azhar","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6501-6196","authenticated-orcid":false,"given":"Vitaliy","family":"Voznyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2243-1916","authenticated-orcid":false,"given":"Mouad","family":"Elganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0204-6497","authenticated-orcid":false,"given":"Chris","family":"Zajner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Juncal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-1857","authenticated-orcid":false,"given":"Thomas G.","family":"Sheidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monali S.","family":"Malvankar-Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.05.010_bib0001","article-title":"Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment","volume":"14","author":"Vyawahare","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.preteyeres.2017.03.002","article-title":"The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD","volume":"60","author":"Datta","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.1009599","article-title":"Exploring the pathogenesis of age-related macular degeneration: a review of the interplay between retinal pigment epithelium dysfunction and the innate immune system","volume":"16","author":"Wong","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0005","article-title":"Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0006","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ophtha.2010.08.044","article-title":"Prevalence of age-related macular degeneration in old persons: Age, Gene\/environment Susceptibility Reykjavik Study","volume":"118","author":"Jonasson","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0007","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0008","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.survophthal.2023.10.010","article-title":"Systematic review of prognostic factors associated with progression to late age-related macular degeneration: pinnacle study report 2","volume":"69","author":"Hagag","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/opo.12675","article-title":"Risk factors for progression of age-related macular degeneration","volume":"40","author":"Heesterbeek","year":"2020","journal-title":"Ophthalmic Physiologic Optic"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0010","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000041599","article-title":"Risk factors for age-related macular degeneration: updated systematic review and meta-analysis","volume":"104","author":"Babaker","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0011","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0012","series-title":"StatPearls","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins","year":"2025"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0013","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists","volume":"86","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0014","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14779072.2025.2587294","article-title":"Cardiovascular efficacy of tirzepatide: what real-world evidence promises","volume":"23","author":"Nasoufidou","year":"2025","journal-title":"Exp Rev Cardiovasc Ther"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009304","article-title":"Effect of once-weekly exenatide on clinical outcomes according to baseline risk in patients with type 2 diabetes mellitus: insights from the EXSCEL trial","volume":"7","author":"Mentz","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0016","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ejhf.2670","article-title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial","volume":"24","author":"Branch","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0017","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jdi.12607","article-title":"Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes","volume":"8","author":"Kim","year":"2017","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0018","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0019","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration","volume":"132","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaophthalmol.2025.1455","article-title":"Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration","volume":"143","author":"Shor","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0021","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0022","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0023","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0024","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.oret.2025.12.016","article-title":"Rate of age-related macular degeneration in patients prescribed glucagon-like peptide-1 receptor agonists or other weight loss therapy","volume":"10","author":"Myers","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajo.2025.12.015","article-title":"Potential eye disorders in people with and without type 2 diabetes mellitus exposed to GLP-1 receptor agonists: an examination of the FAERS (FDA Adverse Event Reporting System) database","volume":"283","author":"Murray","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0026","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1097\/IAE.0000000000004616","article-title":"Impact of GLP-1 receptor agonists for type 2 diabetes mellitus on the development and progression of age-related macular degeneration","volume":"45","author":"McLaughlin","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0027","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.oret.2025.10.020","article-title":"Glucagon-like peptide-1 receptor agonist use and risk of neovascular age-related macular degeneration in a national cohort study","volume":"10","author":"Allan","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0028","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaophthalmol.2025.3821","article-title":"Glucagon-like peptide-1 receptor agonists and age-related macular degeneration","volume":"143","author":"Ahuja","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0029","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.oret.2025.12.014","article-title":"Impact of glucagon-like peptide-1 receptor agonists on age-related macular degeneration at a tertiary ophthalmology center","volume":"10","author":"Joo","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1416985","article-title":"Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events","volume":"15","author":"He","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0031","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0032","doi-asserted-by":"crossref","first-page":"221","DOI":"10.37349\/eds.2023.00015","article-title":"The protective role of GLP-1 in neuro-ophthalmology","author":"Sheth","year":"2023","journal-title":"Explor Drug Sci"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0033","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0034","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.7150\/ijms.20962","article-title":"GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1\/2-HDAC6 signaling pathway","volume":"14","author":"Cai","year":"2017","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1861940","article-title":"GLP-1 RA improves diabetic retinopathy by protecting the blood-retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway","volume":"2022","author":"Wei","year":"2022","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0036","article-title":"Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1\/Parkin-mediated mitophagy in diabetic retinopathy","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0037","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamaophthalmol.2023.1263","article-title":"Validity of administrative claims and electronic health registry data from a single practice for eye health surveillance","volume":"141","author":"Wittenborn","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.05.010_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"suppl 1","key":"10.1016\/j.jcjo.2026.05.010_bib0039","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.2337\/dc23-S012","article-title":"12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822600205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822600205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:25:29Z","timestamp":1788582329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000841822600205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S000841822600205X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.05.010","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age-related macular degeneration associated with glucagon-like peptide-1 receptor agonist use: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}